Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Proteins | 9 | 2024 | 223 | 2.800 |
Why?
|
| Antioxidants | 6 | 2025 | 443 | 2.440 |
Why?
|
| Mitochondria | 5 | 2024 | 523 | 1.210 |
Why?
|
| Calcium | 3 | 2017 | 491 | 0.890 |
Why?
|
| Potentiometry | 2 | 2023 | 8 | 0.850 |
Why?
|
| Triazoles | 2 | 2021 | 102 | 0.760 |
Why?
|
| Pleural Neoplasms | 4 | 2009 | 57 | 0.730 |
Why?
|
| Mesothelioma | 5 | 2009 | 148 | 0.720 |
Why?
|
| Homeostasis | 5 | 2022 | 192 | 0.690 |
Why?
|
| Inflammation | 4 | 2024 | 758 | 0.690 |
Why?
|
| Imidazoles | 1 | 2021 | 142 | 0.670 |
Why?
|
| Phenols | 1 | 2021 | 107 | 0.660 |
Why?
|
| Drug Design | 1 | 2021 | 186 | 0.630 |
Why?
|
| Calcium Signaling | 3 | 2017 | 107 | 0.620 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 495 | 0.610 |
Why?
|
| Aging | 4 | 2024 | 783 | 0.560 |
Why?
|
| Reactive Oxygen Species | 6 | 2020 | 532 | 0.550 |
Why?
|
| Ear, Inner | 1 | 2017 | 2 | 0.530 |
Why?
|
| Aging, Premature | 1 | 2017 | 6 | 0.520 |
Why?
|
| Hearing Loss | 1 | 2017 | 16 | 0.520 |
Why?
|
| Energy Metabolism | 1 | 2017 | 187 | 0.470 |
Why?
|
| Autoimmunity | 1 | 2015 | 58 | 0.450 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2024 | 193 | 0.450 |
Why?
|
| Mice | 14 | 2025 | 6644 | 0.450 |
Why?
|
| Carnitine O-Palmitoyltransferase | 2 | 2024 | 10 | 0.430 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 7 | 0.420 |
Why?
|
| Killer Cells, Natural | 2 | 2025 | 104 | 0.420 |
Why?
|
| NF-kappa B | 2 | 2014 | 358 | 0.420 |
Why?
|
| Acinetobacter Infections | 1 | 2013 | 29 | 0.400 |
Why?
|
| Acinetobacter baumannii | 1 | 2013 | 40 | 0.390 |
Why?
|
| Neutrophils | 1 | 2013 | 145 | 0.380 |
Why?
|
| Peritonitis | 1 | 2012 | 11 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 279 | 0.360 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2009 | 78 | 0.350 |
Why?
|
| Neoplasms | 3 | 2025 | 1377 | 0.350 |
Why?
|
| Animals | 17 | 2025 | 16992 | 0.350 |
Why?
|
| Mice, Knockout | 5 | 2025 | 1035 | 0.340 |
Why?
|
| Oxidation-Reduction | 3 | 2021 | 457 | 0.330 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2020 | 34 | 0.300 |
Why?
|
| Macrophages | 1 | 2013 | 529 | 0.300 |
Why?
|
| Proteoglycans | 1 | 2009 | 49 | 0.290 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 704 | 0.290 |
Why?
|
| Antiviral Agents | 2 | 2021 | 195 | 0.290 |
Why?
|
| West Nile virus | 2 | 2025 | 78 | 0.270 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 592 | 0.260 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 1 | 2025 | 1 | 0.240 |
Why?
|
| Encephalitis, Tick-Borne | 1 | 2025 | 1 | 0.240 |
Why?
|
| West Nile Virus Vaccines | 1 | 2025 | 5 | 0.240 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 2006 | 14 | 0.240 |
Why?
|
| Schizosaccharomyces | 1 | 2006 | 17 | 0.240 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2025 | 5 | 0.240 |
Why?
|
| Immunologic Surveillance | 1 | 2025 | 10 | 0.230 |
Why?
|
| Tumor Escape | 1 | 2025 | 17 | 0.230 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2006 | 69 | 0.230 |
Why?
|
| Viral Vaccines | 1 | 2025 | 37 | 0.230 |
Why?
|
| Coordination Complexes | 1 | 2025 | 28 | 0.230 |
Why?
|
| Methyltransferases | 1 | 2006 | 68 | 0.230 |
Why?
|
| Gene Silencing | 1 | 2006 | 154 | 0.220 |
Why?
|
| West Nile Fever | 1 | 2025 | 68 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2024 | 34 | 0.220 |
Why?
|
| Cell Communication | 1 | 2025 | 114 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 184 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 241 | 0.200 |
Why?
|
| Electrodes | 1 | 2023 | 59 | 0.200 |
Why?
|
| Electrons | 2 | 2021 | 76 | 0.200 |
Why?
|
| Iron | 1 | 2025 | 251 | 0.200 |
Why?
|
| Oxidative Stress | 2 | 2021 | 1003 | 0.200 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 2676 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 299 | 0.200 |
Why?
|
| Cyclin D1 | 1 | 2022 | 44 | 0.190 |
Why?
|
| Picrates | 1 | 2021 | 7 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 133 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 53 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 1869 | 0.180 |
Why?
|
| Kidney | 1 | 2024 | 372 | 0.170 |
Why?
|
| Cell Cycle | 2 | 2022 | 346 | 0.170 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 306 | 0.170 |
Why?
|
| Amino Acid Sequence | 3 | 2014 | 1180 | 0.170 |
Why?
|
| Asbestos | 2 | 2012 | 57 | 0.160 |
Why?
|
| Electrochemical Techniques | 1 | 2020 | 32 | 0.160 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 1542 | 0.160 |
Why?
|
| Chelating Agents | 1 | 2020 | 52 | 0.160 |
Why?
|
| Tungsten Compounds | 1 | 2020 | 16 | 0.160 |
Why?
|
| Molybdenum | 1 | 2020 | 22 | 0.160 |
Why?
|
| Half-Life | 1 | 2020 | 63 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 78 | 0.150 |
Why?
|
| Molecular Structure | 1 | 2021 | 570 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2025 | 249 | 0.150 |
Why?
|
| Signal Transduction | 2 | 2020 | 2157 | 0.150 |
Why?
|
| Tissue Fixation | 1 | 2019 | 19 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2012 | 456 | 0.150 |
Why?
|
| Cell Separation | 1 | 2019 | 94 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1124 | 0.140 |
Why?
|
| Humans | 15 | 2025 | 43102 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 423 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 2 | 2025 | 127 | 0.140 |
Why?
|
| Mitochondrial Proteins | 2 | 2024 | 118 | 0.140 |
Why?
|
| Flow Cytometry | 1 | 2019 | 411 | 0.130 |
Why?
|
| Sperm Count | 1 | 2017 | 28 | 0.130 |
Why?
|
| Spiral Ganglion | 1 | 2017 | 6 | 0.130 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2017 | 11 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 42 | 0.130 |
Why?
|
| Sperm Motility | 1 | 2017 | 47 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 53 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 59 | 0.130 |
Why?
|
| Acetylcysteine | 1 | 2017 | 57 | 0.130 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 160 | 0.130 |
Why?
|
| Mutation | 2 | 2015 | 1177 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1455 | 0.120 |
Why?
|
| Adiposity | 1 | 2017 | 157 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2019 | 434 | 0.120 |
Why?
|
| Glycolysis | 1 | 2015 | 71 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1596 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 206 | 0.110 |
Why?
|
| Epitope Mapping | 2 | 2011 | 32 | 0.100 |
Why?
|
| Kidney Tubules | 2 | 2024 | 39 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 310 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 55 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 24 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2013 | 53 | 0.100 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 90 | 0.100 |
Why?
|
| Male | 7 | 2024 | 23409 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 87 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 968 | 0.100 |
Why?
|
| Ion Channels | 1 | 2012 | 74 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 91 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 151 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2011 | 74 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 652 | 0.090 |
Why?
|
| Epitopes | 1 | 2011 | 157 | 0.090 |
Why?
|
| Viral Envelope Proteins | 1 | 2011 | 91 | 0.080 |
Why?
|
| Lung | 1 | 2013 | 492 | 0.080 |
Why?
|
| Protein Binding | 1 | 2014 | 1082 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 934 | 0.080 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 1621 | 0.080 |
Why?
|
| Free Radical Scavengers | 1 | 2009 | 64 | 0.080 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2009 | 1 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 267 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2009 | 36 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2009 | 168 | 0.070 |
Why?
|
| Osteopontin | 1 | 2009 | 46 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1070 | 0.070 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2008 | 1 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 20 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 25 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 678 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 131 | 0.070 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2008 | 7 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1271 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 165 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 154 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 665 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 216 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 224 | 0.060 |
Why?
|
| Protein Methyltransferases | 1 | 2006 | 6 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 712 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2006 | 29 | 0.060 |
Why?
|
| Vaccines, Inactivated | 1 | 2025 | 18 | 0.060 |
Why?
|
| Electrophoresis | 1 | 2006 | 24 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2025 | 12 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1081 | 0.060 |
Why?
|
| Deoxyribonucleases | 1 | 2006 | 27 | 0.060 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2006 | 31 | 0.060 |
Why?
|
| Monitoring, Immunologic | 1 | 2025 | 6 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2006 | 150 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2025 | 53 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2006 | 196 | 0.060 |
Why?
|
| Cell Movement | 1 | 2009 | 655 | 0.060 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2024 | 4 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 90 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2024 | 141 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 455 | 0.050 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 5 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2025 | 694 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2024 | 77 | 0.050 |
Why?
|
| Phosphates | 1 | 2023 | 54 | 0.050 |
Why?
|
| RNA | 1 | 2006 | 266 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2024 | 171 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 62 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2024 | 134 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 306 | 0.050 |
Why?
|
| Russia | 2 | 2017 | 29 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Astrocytes | 1 | 2024 | 244 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 61 | 0.040 |
Why?
|
| Electricity | 1 | 2021 | 12 | 0.040 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2021 | 41 | 0.040 |
Why?
|
| Electrochemistry | 1 | 2021 | 38 | 0.040 |
Why?
|
| Hippocampus | 1 | 2024 | 594 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2024 | 561 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 423 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 187 | 0.040 |
Why?
|
| Aristolochic Acids | 1 | 2019 | 1 | 0.040 |
Why?
|
| Polyploidy | 1 | 2019 | 8 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2019 | 68 | 0.040 |
Why?
|
| Neutralization Tests | 2 | 2011 | 57 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 148 | 0.040 |
Why?
|
| Female | 4 | 2025 | 24698 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2017 | 7 | 0.030 |
Why?
|
| Economics | 1 | 2017 | 7 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 876 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 23 | 0.030 |
Why?
|
| Aged | 3 | 2022 | 8214 | 0.030 |
Why?
|
| Stents | 1 | 2017 | 67 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 1472 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 210 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2009 | 536 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 247 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 2011 | 20 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 2853 | 0.020 |
Why?
|
| Pleura | 1 | 2009 | 5 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 75 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 139 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2009 | 94 | 0.020 |
Why?
|
| Asbestosis | 1 | 2008 | 7 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 49 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 159 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 80 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 238 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 368 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 374 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 575 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 667 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 611 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 526 | 0.010 |
Why?
|
| Hybridomas | 1 | 2005 | 24 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 861 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2005 | 48 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2005 | 87 | 0.010 |
Why?
|
| Vero Cells | 1 | 2005 | 112 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 863 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1285 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 12222 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 883 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2008 | 2544 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 1019 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 13872 | 0.010 |
Why?
|